Bicara Therapeutics Inc. (BCAX): Cash & Equivalents
$96.69M
As of 2025-12-31
$96.60M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $96.69M | -80.3% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $489.71M | +112.5% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $230.44M | n/a | 2025-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $96.69M | -80.3% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $42.91M | -39.9% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $9.82M | 0.0% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $334.52M | +85.4% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $84.22M | -34.2% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $373.69M | n/m |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| Biohaven Ltd. (BHVN) | 2025-12-31 | $229.96M | +132.0% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $45.67M | -23.1% |
Compare BCAX, ARQT, BGM, MLTX side by side · Screen every company in Pharmaceutical Preparations ↗